This conference uniquely brings together members of the financial community and business leaders from established and emerging companies in the dermatology space to help foster investment and partnerships in the next generation of dermatology companies and products.
Dr. Azimi is Bioniz' founder and the co-inventor of its core technology and has served as Company’s President and CEO since its inception. Dr. Azimi is a graduate of University of Tehran and recipient of a post-doctoral fellowship program in immunology at one of the premier research groups at the National Cancer Institute, National Institutes of Health (NIH) where she studied cytokine biology. During her training and later as an independent scientist, she made seminal contributions to the field, and developed the knowledge and the idea that later became the foundation for Bioniz's multi-cytokine inhibitory platform technology.
After completing her training at the NIH, Dr. Azimi joined the faculty at the Fred Hutchinson Cancer Research Center where she studied immune cytokine responses to viral infection. Prior to founding Bioniz, Dr. Azimi served as founder and CEO of Dermaheal USA, a privately held dermatology company. Dr. Azimi has authored over 40 peer-reviewed, high impact scientific publications and is the inventor of more than a dozen patents, including the Bioniz intellectual property patent estate. She is an advisor to the Dean of Pharmacy School at the Chapman University and the recipient of 2017 EY Winning Women.
Carrie Caulkins is the Global Head of Strategic Marketing for the Aesthetics Business at Galderma. She oversees the aesthetic franchise global business strategy, pipeline, and lifecycle management of pharmaceutical & medical device brands. Carrie has broad US and global experience in developing and launching new products based on customer insights, strong cross-functional collaborations, and building of high-performance teams. The past 10 years of her career have focused on medical aesthetics including at Allergan as a Senior Manager of global marketing in facial aesthetics. She has further held several roles within Medical Affairs at Allergan for facial aesthetics and neurology, and took a cosmeceutical product from bench-top to market at the start-up company Invitrix.
Carrie earned her MS and PhD in Biomedical Engineering from the University of California, Los Angeles, an MBA from the University of California, Irvine, and a bachelor's in science degree in biomedical engineering from Brown University.
David Domzalski has served as Chief Executive Officer since July 2017. Mr. Domzalski has been with Foamix since April 2014, and previously served as President of Foamix Pharmaceuticals Inc. (US subsidiary). He has 25 years of industry experience, previously holding positions as Vice President, Sales and Marketing, at LEO Pharma Inc. from 2009 to 2013, Senior Vice President and General Manager at Azur Pharma from 2008 to 2009, and Vice President, Sales and Marketing, at Warner Chilcott from 2003 to 2008. Mr. Domzalski holds a BA in economics and political science from Muhlenberg College, Allentown, Pennsylvania.
Mark Foley is currently the President and CEO of Revance Therapeutics and has served as a member of the Company’s board of directors since September 2017.
Previously, Mr. Foley was Chairman, President and CEO of ZELTIQ Aesthetics (ZLTQ). During his tenure, he led ZELTIQ's growth from $68 million in annual revenue in 2012 to over $350 million in 2016, resulting in an appreciation of the Company’s stock of greater than tenfold and acquisition by Allergan (AGN) in April of 2017 for $2.5B. Mr. Foley also served as a Managing Director of RWI Ventures, a venture capital firm focused on life sciences, networking, semiconductor and software investments, from 2004 to 2018.
Mr. Foley has over 25 years of experience in the health care field, having served in a variety of senior operating roles in both large public companies and venture-backed startups, including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic), where he was the founder and CEO. Also, he has partnered with a number of entrepreneurs to assist with the formation and capitalization of new health care companies while also serving as a Senior Advisor, Executive Chairman, interim CEO and board member to a number of medical device companies.
Mr. Foley currently serves on the board of directors of Glaukos (GKOS), Si-Bone (SIBN) and as chairman of the board for ULab and HintMD. He also co-chairs the Aesthetics Innovation Summit and was chairman of Arrinex up and until its acquisition by Stryker in the spring of 2019. Mr. Foley received his BA from the University of Notre Dame in 1987 and is a named inventor on 17 patent applications.
Peter Guenter is Chief Executive Officer of Almirall SA since October 1st, 2017. He is also member of the board of EFPIA (European Federation of Pharmaceutical Industries and Associations) and member of the board of Galapagos NV, a leading biotechnology company.
He started his career in Smith Kline (now Glaxo Smith Kline) and later worked for Novartis.
He entered in 1995 in the Sanofi Group, where he would spend 22 years of his professional life, in job assignments with increasing responsibilities, amongst others General Manager Belgium, Vice President Eastern and Northern Europe, General Manager Germany, Senior Vice President Europe, Executive Vice President Global Commercial Operations, Executive Vice President General Medicine and Emerging Markets, Executive Vice President Diabetes and Cardiovascular.
He has been member of Sanofi’s Executive Committee from 2013 till 2017.
He holds a Master’s Degree in Physical Education from the Faculty of Medicine and Health Sciences, University of Ghent, Belgium.
Bio Coming Soon
Michael Mazen Jafar joined Evolus™ as Chief Marketing Officer in June 2018. Mr. Jafar joins the organization with nearly 15 years of commercial and executive experience building multiple market leading brands such as JUVÉDERM VOLUMA® and CoolSculpting®.
Mr. Jafar formerly served as Vice President of Marketing, U.S. Medical Aesthetics at Allergan. Prior to that, he led the assessment and integration of ZELTIQ® along with the strategic marketing for Allergan’s aesthetic portfolio of brands, including Botox® Cosmetic, JUVÉDERM® Collection, KYBELLA®, Natrelle®.
Mr. Jafar is a board member of the Irvine Public School Foundation, an Orange County based philanthropic organization. He holds an MBA from University of Southern California and a B.A. in International Finance and Supply Chain from the University of San Diego.
Rachna Khosla is a Vice President in Business Development at Amgen. She leads a team that is responsible for corporate development, strategic collaborations, M&A and licensing/out-licensing activities. In 2019 her team was responsible for both the Otezla and Nuevolution acquisitions. Rachna joined Amgen in 2013.
Rachna brings over 26 years of experience in strategic biopharmaceutical deal-making. Previously, Rachna held leadership positions as a healthcare M&A investment banker at Lazard Freres & Co., Credit Suisse, JPMorgan and Salomon Brothers. She has announced deals over $150B in total value. Rachna also spent 2.5 years at Aventis Capital, Aventis’ corporate venture capital arm, where she was a member of the investment committee and managed a portfolio of assets worth over a $1B.
Rachna received her MBA from Columbia Business School and her BA from Barnard College, Columbia University. She attended the London School of Economics for one year while at Barnard.
Rachna serves as a member of the Healthcare Sector Advisory Board for the Partnership Fund for New York City, whose mission is "to create jobs, spur new business creation and to expand opportunities for all of the city’s residents and neighborhoods. The fund invests exclusively in NYC based ventures -both for-profit and non-profit."
In her spare time Rachna enjoys yoga, learning to surf, reading and photography. She completed the Yogaworks 200-hour teacher training course and is a certified yoga instructor.
Brett Kopelan was initiated into the world of rare diseases eleven years ago when his daughter was born with a severe form of recessive dystrophic epidermolysis bullosa (RDEB). Shortly after her birth, Brett was elected to the board of directors of the Dystrophic Epidermolysis Bullosa Research Association of America (debra of America), the only national not-for-profit providing all-inclusive support to the EB community. Upon returning to New York City after his daughter was the 8th child in the world to undergo a stem cell transplant in hopes of treating her RDEB at the University of Minnesota, he became the Executive Director of debra of America. Prior to his rare disease work, Brett was an accomplished entrepreneur, starting three different companies raising more than $30 million in venture financing, where he led business development and marketing. He has a graduate degree from Columbia University and an undergraduate degree from New York University.
Brett currently serves as President of the board of directors of Debra International (a consortium of 55 nongovernmental organizations dedicated to curing EB), sits on the board of directors of the Alliance for Regenerative Medicine Foundation, and serves as Vice President and Secretary on a 50-year-old financial services firm’s board of directors. Brett formerly served as both the Chairman of the board of directors, and as the Treasurer of the National Organization for Rare Disorders (NORD) and as President of the board of directors of the Coalition of Skin Diseases.
Suma Krishnan is the Founder and Chief Operating Officer at Krystal Biotech (NASDAQ: KRYS). She has over 25 years of drug development experience. Prior to Krystal she was Head of Human Therapeutic Division at Intrexon Corporation (NASDAQ:XON), where she delivered on multiple gene therapy programs from discovery to clinic. Previously she led discovery, development and approval of Vyvanse (blockbuster drug for ADHD) as Sr. VP of New River Pharmaceutical (acquired by Shire). She began her career as a discovery scientist at Janssen Pharmaceuticals. She has over 20 issued patents and over 50 publications. She has her Masters in Organic Chemistry and Masters in Business Administration.
Paresh Lala is a Managing Director at Dyal Co. LLC, an independent boutique mergers and acquisition advisory firm. Paresh has over 15 years of experience in M&A and investment banking. Paresh joined Dyal Co. as a founding member of the team in 2016 and leads the firm's Healthcare / Biopharma client coverage efforts. Selected transaction experience at Dyal Co. includes Bristol-Myers Squibb’s acquisition of Celgene, Amgen’s acquisition of Otezla and Novartis' acquisition of AveXis.
Prior to joining Dyal Co., Paresh spent 8 years in the Healthcare Investment Banking Group at Goldman, Sachs & Co. in New York. His primary experience was in covering clients in the Biopharma and Medical Devices sectors. Prior to Goldman Sachs, Paresh spent three years at CIBC World Markets in Toronto. Paresh earned a B.B.A. from York University and an M.B.A. from New York University.
Jesper J. Lange is co-founder of MC2 Therapeutics and joined the company from his position as partner in a major law firm representing both investors and innovative companies.
Based on this experience and strong entrepreneurial skills Jesper is focused on bringing together the expertise of people and companies through a fundamental belief in inclusion as the main driver of passion, innovation and high performance.
Jesper holds a Master of Law (LLM) degree from Columbia University Law School in New York.
Tim Lugo, partner, joined William Blair in 2005 and focuses on the therapeutics space. Before joining William Blair, he worked at Pacific Growth Equities as a junior analyst on a number of specialty pharmaceutical companies. Mr. Lugo was named No. 1 stock picker and No. 3 earnings estimator in the 2016 Thomson Reuters Analyst Awards for his coverage of biotechnology. Mr. Lugo has a B.A. in molecular and cellular biology (with an emphasis in genetics) and a B.A. in economics, both from the University of California, Berkeley.
Peter Marinkovich has been dedicated to the study of epidermolysis bullosa his entire career. During his research training, he studied under Dr. Robert Burgeson, who discovered type VII collagen, the deficient protein in dystrophic EB. With Dr. Burgeson, Dr. Marinkovich helped to discover and characterize laminin-332, the protein affected in most junctional EB patients. Dr. Marinkovich initially developed his clinical expertise in EB while serving as an attending member of the national EB registry, along with Drs Eugene Bauer and Joseph McGuire during the 1990’s. Since 1995, Dr. Marinkovich has directed the Bullous Disease Clinic at Stanford University. He is also a longstanding member of the EB classification consensus group and has authored over 100 peer reviewed articles on basic and clinical aspects of basement membrane zone biology and blistering diseases. He writes the chapters on epidermolysis bullosa for Fitzpatrick’s Dermatology in General Medicine, WebMD and E-medicine. Dr. Marinkovich had led an NIH sponsored basic research laboratory for many years focusing on epidermolysis bullosa and basement membrane zone biology. Currently his laboratory and clinical research teams are engaged in a number of molecular gene and protein therapy studies in junctional and dystrophic epidermolysis bullosa.
Mr. Maslowski serves as Fibrocell’s President and Chief Executive Officer. Prior to that, he was Senior Vice President of Scientific Affairs, with oversight of research and development, clinical and regulatory affairs. Previously, he was Vice President of Operations with responsibility for manufacturing and quality operations. Prior to joining Fibrocell, Mr. Maslowski held various positions at Wyeth Pharmaceuticals, Inc. (now Pfizer, Inc.), eventually serving as Quality Assurance Manager. Prior to joining Wyeth, Mr. Maslowski held various positions with Merck & Co. and Teva. Mr. Maslowski earned a B.S. in Biology from the Ursinus College and an M.S. in Biology from Villanova University.
Raymond A. Miller is a partner and vice chair of the Health Sciences Department of Pepper Hamilton LLP, resident in the Pittsburgh office. A registered patent attorney, Mr. Miller focuses his practice on identifying, protecting, securing and maximizing the value of clients’ intellectual property. Mr. Miller’s clients include universities, research institutes and businesses ranging from idea stage through Fortune 500 companies, as well as other organizations and individuals involved in basic research and technology transfer. He has represented Ivy League universities, research organizations, pharmaceutical companies, biotechnology companies, consumer products companies, manufacturing companies, computer software developers and R&D contractors. His practice includes both prosecution and transactional IP, including acquiring and licensing patents, trademarks, copyrights and trade secrets, as well as litigation.
Mr. Miller's practice includes an array of chemical, medical, pharmaceutical, mechanical, environmental and business method fields. While he is particularly adept at handling technologies in the life sciences, he also is proficient in areas of material sciences, metallurgy, thin-film technology, specialty chemicals, polymer chemistry, nanotechnology and cosmetics.
Mr. Miller is a Chambers USA recognized practitioner; recommended in IAM Patent 1000, a guide to the world's leading patent professionals; named an Acritas Star 2018-19; and is listed in The Best Lawyers in America. Mr. Miller is a member of the American Association for the Advancement of Science, the Association of University Technology Managers, Inc. and the American Intellectual Property Law Association. He has published numerous peer-reviewed articles in academic and scientific journals.
David Moatazedi joined Evolus as President and Chief Executive Officer in May 2018. Mr. Moatazedi formerly served as Senior Vice President of U.S. Medical Aesthetics at Allergan™, leading the entire aesthetic portfolio of brands including Botox® Cosmetic, JUVEDERM® Collection, CoolSculpting®, KYBELLA®, SkinMedica®, Latisse®, Natrelle® and Alloderm®.
Mr. Moatazedi has nearly twenty years of commercial and executive experience building multiple market leading brands. David also led several acquisitions for Allergan, including LifeCell™ for $2.9B and ZELTIQ® Aesthetics for $2.5B.
Prior to Mr. Moatazedi’s thirteen years at Allergan he spent six years at Novartis Pharmaceuticals. He holds an MBA in Marketing from Pepperdine University and a B.A. in Chemistry from California State University, Long Beach.
Luis is a co-founder of Dermira and serves as our Chief Development Officer. In this role, Luis oversees Regulatory and Research and Development. He has nearly 30 years of product development and portfolio management experience. Prior to joining Dermira, Luis served as Vice President, Head of Global Prescription Development at Stiefel, a GSK company, and was Senior Vice President Portfolio Planning and Management at Stiefel Laboratories prior to its acquisition by GlaxoSmithKline, Inc. He also held leadership roles in portfolio management and product development at Connetics and Theravance, Inc. as well as various positions in manufacturing and research and development at Genentech, Inc. Luis holds a B.S. in biochemistry from San Francisco State University.
Sanuj K. Ravindran, M.D. is President and CEO of PellePharm. Dr. Ravindran also serves on the PellePharm Board of Directors, and is CEO-in-Residence with BridgeBio, PellePharm's parent company.
Dr. Ravindran has more than 15 years of strategic and operational biopharma experience. Previously, he was chief business officer at aTyr Pharma (“LIFE”), a clinical stage rare disease-focused biotechnology company, where he led corporate strategy, financial strategy, business development, and investor relations. Prior to that, Dr. Ravindran was senior vice president of corporate development for The Medicines Company (“MDCO”), where he worked to execute multiple transactions totaling more than $2 billion in potential aggregate value. Previously a practicing physician, Dr. Ravindran began his industry career as a venture capitalist for 10 years with Burrill & Company, Radius Ventures, and Asian Healthcare Fund.
Dr. Ravindran is trained in Internal Medicine and completed his residency training at Thomas Jefferson University Hospital. Dr. Ravindran received his B.A. from Northwestern University, his M.D. from Jefferson Medical College and his MBA from the Kellogg School of Management.
João Siffert, MD, joined Abeona as Head of Research and Development and Chief Medical Officer in 2018, bringing 30 years of combined experience in the biopharmaceutical industry, clinical care, and academia. In February 2019, he was appointed Chief Executive Officer after serving in the role on an interim basis from November 2018. In February 2019, he was also appointed to the Board of Directors. Dr. Siffert has successfully led multiple drug development programs from pre-clinical to regulatory approvals and commercial launches in the U.S. and Europe and has held several scientific leadership positions in biotech and pharma, including programs in gene therapy.
In 2017, Dr. Siffert was appointed to the Board of Directors of gene therapy developer AveXis Inc., which was subsequently acquired by Novartis. Dr. Siffert began his career in industry at Pfizer, where he held medical roles of increasing responsibility from 2002 to 2005. He served as Chief Medical Officer of Avera Pharmaceuticals from 2005 to 2007, before holding the same position at Ceregene from 2007 to 2011, where he was responsible for clinical development of adeno-associated viral (AAV2)-based gene therapies for Parkinson's and Alzheimer's diseases. Dr. Siffert also led the R&D, medical, regulatory, compliance, manufacturing and quality organizations at Avanir Pharmaceuticals from 2011 to 2016. Most recently, he was the Chief Scientific and Medical Officer for Nestle Health Science, where he led translational research, clinical development and operations, regulatory, medical affairs, and health economics. Before joining industry, Dr. Siffert spent seven years in academic practice as a neuro-oncologist.
Dr. Siffert earned his M.D. from the University of São Paulo, Brazil, as well as an M.B.A. from Columbia University. He completed medical residencies in pediatrics at New York University (NYU) School of Medicine and in neurology at Harvard Medical School, followed by a fellowship in neuro-oncology at NYU. The American Board of Neurology and Psychiatry certified Dr. Siffert in 1996.
Carrie Strom is Senior Vice President, U.S. Medical Aesthetics at Allergan and has served in the role since May 2018, overseeing the entire aesthetic portfolio for the multi-billion dollar U.S. business including the marquee brand BOTOX Cosmetic, the Juvéderm Family of Fillers, Kybella, CoolSculpting, SkinMedica, Latisse, Natrelle Implants and Tissue Expanders, Keller Funnel, Alloderm, Strattice and Revolve.
Previously, Carrie was Vice President of Marketing, Plastic Surgery and Regenerative Medicine, which posted a record high growth rate in 2017. In that role, Carrie was instrumental in the $2.8B acquisition and integration of LifeCell. Prior to that, Carrie led SkinMedica Marketing and worked on BOTOX Therapeutic in Urology and Neurology at Allergan. Before Allergan, Carrie spent 11 years at Pfizer, Inc in NYC in sales and marketing roles, with most of her time spent leading marketing for LIPITOR.
Carrie is an advocate for women in business and is actively involved with the Girls, Inc. organization. She serves on the board of directors for Susan G Komen of Orange County, CA. Carrie lives in Newport Beach, CA with her husband and two children.
Dolca Thomas is the Chief Medical Officer at Principia Biopharma. Prior to joining Principia, Dr. Thomas was Vice President and Global Head of Translational Medicine for Immunology, Inflammation, and Infectious Disease at Roche, where she was responsible for advancing multiple product candidates through clinical development. Prior to Roche, Dr. Thomas held roles of increasing responsibility at Pfizer, including Vice President of Clinical Development and Clinical Immunophenotyping, and Vice President and Chief Development Officer of the Biosimilars Research and Development Unit where she was responsible for all stages of development of multiple assets. Dr. Thomas began her industry career at Bristol-Myers Squibb as Director of Global Clinical Development in Immunology, where she was involved in the development and approval of belatacept. Dr. Thomas has been on faculty at Weill Cornell Medical-New York Presbyterian Hospital Department of Nephrology and Transplantation and at the St. Luke’s-Roosevelt Hospital Transplant Center in New York City. Dr. Thomas received her B.A. in sociology and her M.D. from Cornell University.
Thorsten Thormann is Vice President of Research in LEO Pharma, a function that builds and maintains a strong R&D project pipeline. Thorsten has over 20 years of experience within biomedicine and drug research and he and his team has over the past years brought a number of molecules from research and into clinical testing. This has resulted in two marketed products and several of programs currently in clinical development.
Prior to being Vice President of Research, Thorsten has over the years held a number of leadership positions within LEO Pharma aiming to build translational drug discovery platforms in dermatology as well as refocusing the early formulation and CMC to build a platform for product improvements based on usability and patient driven innovation.
Additionally Thorsten is currently responsible for building the LEO Pharma’s pipeline and organizational unit within rare skin diseases.
Thorsten Thormann has a scientific background with a MSc in Chemistry and a PhD in Protein Biology.
Ted White has served as President and Chief Executive Officer of Verrica Pharmaceuticals since December 2017 and as a member of the board of directors since May 2018. Previously, from January 2011 to September 2017, Mr. White was the President and General Manager at Almirall, a global pharmaceutical company based in Barcelona, Spain with a focus on medical dermatology, the parent company of Aqua Pharmaceuticals. Prior to Aqua Pharmaceuticals, Mr. White was at Novartis from 1989 to 2010, where he served in a number of leadership roles, most recently as a Managing Director. Mr. White holds a M.B.A. from St. Joseph’s University and a B.A. in General Arts from Villanova University.
Todd Zavodnick has served as Dermavant Chief Executive Officer since November 2018 and as a member of the Company's board of directors since May 2019. Mr. Zavodnick has over 20 years of leadership experience in the biopharmaceutical industry. Prior to joining Dermavant in November 2018, Mr. Zavodnick served as Chief Commercial Officer at Revance. He previously served in global leadership roles at ZELTIQ Aesthetics prior to the company’s acquisition by Allergan, at Galderma Laboratories where he was President and General Manager of North America, and at Alcon Laboratories. He is a member of the board of directors of the Children's Skin Disease Foundation and Allurion. Mr. Zavodnick received a B.S. in Pharmacy from Rutgers University and an M.B.A. from The University of Texas at Dallas.
Frederick C. Beddingfield III is founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. He started Sienna in 2016 and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he led the development of global leading brands in medical dermatology and aesthetics including Botox, Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. He has led multiple successful FDA advisor committees.
Since completing his training, Frederick has always maintained a clinical and teaching practice at UCLA where he is an Associate Clinical Professor. He is a board-certified dermatologist and emergency medicine physician and a fellowship trained dermatologic surgeon. Frederick completed his medical degree at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder.
John Doux, MD obtained a B.S. with distinction and an MD from Stanford University, where he was a Howard Hughes Medical Institute Fellow performing research in the laboratory of Dr. David Woodley. After an internship at Brigham and Women's Hospital in Boston, he returned to Stanford to complete his residency training in dermatology. He also completed an MBA at the Wharton School of Business where he was a Palmer Scholar. He is board certified in dermatology and maintains an active clinical practice. Since 2004 he has also served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare with $2B+ in assets under management.
William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a co-founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development and leadership functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.
Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology under Douglas Lowy, M.D. and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University. Dr. Ju is a co-founder of EdWiser, Inc. (now known as Zoomi, Inc.), is currently a member of the board of directors for Brickell Biotech, Inc., and serves on the Advisory Council for the Keller Center for Innovation Engineering Education at Princeton University.
Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.
Dr. Walker co-founded Aclaris Therapeutics, Inc. and has served as its President and CEO and a member of the board of directors since 2012. He is a board-certified dermatologist and serial entrepreneur with over 20 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson. Dr. Walker co-founded NeXeption LLC, a biopharmaceutical assets management company, in 2012. He co-founded and served as president and CEO and a member of the board of directors of Vicept Therapeutics Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan in 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture); Trigenesis Therapeutics Inc., a specialty dermatology company, where he served as chief medical officer (acquired by Dr. Reddy's Laboratories Ltd.); and Cutix Inc., a commercial dermatology company. He also co-founded and continues to serve on the board of directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is on the board of directors of Aldeyra Therapeutics Inc., a publicly held biotechnology company, as well as Life Sciences Pennsylvania and several private companies. In 2016, Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award and the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology. He received a Bachelor of Arts in biology from Lehigh University, a Master of Business Administration from The Wharton School, University of Pennsylvania, and a Doctor of Osteopathic Medicine from the Philadelphia College of Osteopathic Medicine.
Albert Cha, MD, PhD. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND), BioHaven Pharmaceuticals (NYSE: BHVN), KalVista Pharmaceuticals (NASDAQ: KALV), Menlo Therapeutics (NASDAQ: MNLO).
He was an investor in Aclaris Therapeutics (NASDAQ: ACRS), AirXpanders (ASX: AXP), ProNAi Therapeutics (NASDAQ: DNAI), Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG). Albert is also a co-founder and board member of the annual Dermatology Summit and Dermatology Innovation Forum. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.
The Dermatology Summit utilizes a conference app for meeting materials and networking appointments, available on both Apple and Android devices for all registered attendees.
This app will also serve as our networking portal. Upon logging into the app, you will be able to network with other attendees and set up meetings in our 1:1 conference networking space.
Our app will launch in December, and you will receive an email at that time with download instructions.
Palace Hotel, San Francisco
2 New Montgomery Street,
San Francisco, CA 94105
The current program agenda can be found here.
Conference registration includes:
If you are interested in a sponsorship opportunity, please contact Rhonda Ware at firstname.lastname@example.org, for the sponsorship overview and level pricing.
All deliverables for confirmed speakers can be found here.
Our app will launch in December, and you will receive an email at that time with download instructions to network with other conference attendees and set up 1:1 meetings in our dedicated networking space.
There are several hotels within a short distance from the Palace Hotel, where the Dermatology Summit will take place. Please reference the list of hotels below for booking your own hotel room. The Dermatology Summit does not have contracted rates with these hotels.
|Palace Hotel||2 New Montgomery Street||415-512-1111|
|Grand Hyatt San Francisco||345 Stockton Street||415-398-1234|
|Sir Francis Drake||450 Powell Street||415-392-7755|
|Westin St. Francis||335 Powell Street||800-937-8461|
|JW Marriott||510 Mason Street||415-771-8600|
|Stanford Court Hotel||905 California Street||415-989-3500|
|Prescott, A Kimpton Hotel||545 Post Street||415-563-0303|
|Hilton San Francisco Union Square||333 O'Farrell Street||415-771-1400|
|Ritz-Carlton||600 Stockton Street||415-296-7465|
|InterContinental Mark Hopkins||999 California Street||415-392-3434|
|The Clift Hotel||495 Geary Street||415-775-4700|
|Serrano Hotel||405 Taylor Street||415-885-2500|
|Marriott Union Square||480 Sutter Street||415-398-8900|
Attire is business casual. Feel free to be comfortable in slacks, polo shirts, blazers, blouses and most importantly, comfortable shoes. We do recommend you dress in layers as temperatures in meeting rooms can vary.
After your sponsorship has been processed, you will receive an email with a unique code and instructions to register online. We encourage all complimentary and discounted registrations to be completed by December 11, 2019. If you have not yet received the email, please contact us at email@example.com.
Requests for registration fee cancellations for the conference must be received on or before December 6, 2019 by 3pm Eastern Time. At the discretion of the conference organizers, a refund via the method of original payment, minus a $125 non-refundable administrative fee, will be issued. No refunds will be made if notice is received after 3pm Eastern Time on December 6, 2019. Written notice of your cancellation should be sent to firstname.lastname@example.org with a copy to email@example.com.
No damages or refunds shall be due for a failure of performance by the occurrence of any contingency beyond the reasonable control of AID or Eclipse Meeting Productions. These contingencies include, without limitation, threat of or actual war, terrorism, sabotage, insurrection, riot or other act of civil disobedience, act of public enemy, failure or delay in transportation, act of government or any agency affecting the terms of this Agreement, accident, fire, explosion, flood, severe weather, natural disaster, or other act of God, interruptions or failure of the Internet or third-party network connections, or acts beyond the reasonable control of the responsible parties making the Event impossible to hold.
Advancing Innovation in Dermatology, Inc. is a registered IRS 501(c)(3) organization designated as a public charity in the United States.